Q3 2024 SiC Patent Monitor Report: over 850 new patents, 20 new entrants, and 11 notable IP collaborations identified

SOPHIA ANTIPOLIS, France – November 6, 2024 │ The quarterly report for Q3 2024 SiC Patent Monitor is now available. This monitoring service allows you to keep up to date on SiC-related patent activity for power electronics: new patent applications, patents newly granted, expired or abandoned patents, latest patent transfers, patent litigations and oppositions. Overview[…]

Significant rise in mRNA technology intellectual property activity: A third quarter of innovation observed in 2024

SOPHIA ANTIPOLIS, France – October 09, 2024 │ Amidst the rapidly evolving landscape of medical biotechnology, especially in the therapeutic RNA sector, groundbreaking advances continue to reshape the field. The latest release of our Therapeutic mRNA patent monitor delivers comprehensive insights, underscoring a notable acceleration in intellectual property developments, pushing the boundaries of RNA-based treatments[…]

Featured image of the article Hybrid bonding: A global picture of the IP competition

Hybrid bonding: A global picture of the IP competition

SOPHIA ANTIPOLIS, France – September 09 2024 │ KnowMade, a leading provider of patent analysis services, is proud to announce the release of its latest report, Hybrid Bonding Patent Landscape Analysis 2024. This comprehensive report provides a detailed examination of the competitive landscape of the hybrid bonding technology from a patent perspective, offering critical insights[…]

Featured image of the article Q2 2024 IP Activity Reveals New Granted Patents in mRNA Delivery and a Newcomer Developing Therapeutic Circular RNA for Pet Vaccination.

Q2 2024 IP Activity Reveals New Granted Patents in mRNA Delivery and a Newcomer Developing Therapeutic Circular RNA for Pet Vaccination

SOPHIA ANTIPOLIS, France – September 03, 2024 │ The quarterly report for the Q2 2024 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. What’s new this quarter? Q2 2024 patenting activity maintains steady pace with notable new granted patents in[…]